Zai Lab Upsizes Follow-on Public Offering to $200 Million
Zai Lab Ltd. (Nasdaq: ZLAB) announced Friday it increased its secondary public offering to 7.8 million American depositary shares, sending its stock nearly 4 percent higher intraday to $26.70 per share.
The developer and distributor of medicines for cancer and infectious diseases said the offering was expected to close on May 7.
The company said in an official news release that the gross proceeds to Zai Lab from the offering will be approximately $200 million. The amount doesn't include the underwriting expenses, commissions and other offering expenses.
Earlier this week, the Shanghai-based biopharma company said it sought to sell 5 million ADSs and offered an additional 750,000 shares for over-allotment to the underwriters,
Zai Lab reached commercial stage in 2018, launching two drugs, Zejula and Optune, in Hong Kong. Its niraparib's NDA submission is under review in China, according to a March statement. The company has said it anticipates a potential launch in the second half of 2019.
Trip.com Announces Joint Venture With TripAdvisor
Nio and Intel to Jointly Launch L4 Model
Bright Scholar's Shares Slip 2% on Losses, Market Uncertainty
36Kr Raises $20 Million in New York IPO; Stock Tumbles on Debut
Pingtan Stock Plunges 14% on Weak Sales, Net Income Drop
500.com Posts Disappointing Revenue for Third Quarter